These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26406865)

  • 1. Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer.
    Nakashima M; Matsui Y; Kobayashi T; Saito R; Hatahira S; Kawakami K; Nakamura E; Nishiyama H; Ogawa O
    Cancer Biomark; 2015; 15(4):357-64. PubMed ID: 26406865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic role of urinary collagens in primary human bladder cancer.
    Miyake M; Morizawa Y; Hori S; Tatsumi Y; Onishi S; Owari T; Iida K; Onishi K; Gotoh D; Nakai Y; Anai S; Chihara Y; Torimoto K; Aoki K; Tanaka N; Shimada K; Konishi N; Fujimoto K
    Cancer Sci; 2017 Nov; 108(11):2221-2228. PubMed ID: 28837258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
    Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
    Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre and postoperative quantitative detection of fragments of cytokeratins 8 and 18 (UBC IRMA) as markers of early recurrence of superficial bladder tumor.
    Gacci M; Serni S; Lapini A; Giubilei G; Dal Canto M; Paladini S; Curotto A; Gallo F; Carmignani G; Carini M
    Arch Ital Urol Androl; 2006 Mar; 78(1):5-10. PubMed ID: 16752880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer.
    Kawanishi H; Matsui Y; Ito M; Watanabe J; Takahashi T; Nishizawa K; Nishiyama H; Kamoto T; Mikami Y; Tanaka Y; Jung G; Akiyama H; Nobumasa H; Guilford P; Reeve A; Okuno Y; Tsujimoto G; Nakamura E; Ogawa O
    Clin Cancer Res; 2008 May; 14(9):2579-87. PubMed ID: 18451219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic value of bladder cancer-related transcript markers in urine.
    Schmidt J; Propping C; Siow WY; Lohse-Fischer A; Toma M; Baldauf-Twelker A; Hakenberg OW; Wirth MP; Fuessel S
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):401-14. PubMed ID: 26328914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging.
    Shkolyar E; Zhao Q; Mach KE; Teslovich NC; Lee TJ; Cox S; Skinner EC; Lu Y; Liao JC
    Urol Oncol; 2021 Aug; 39(8):497.e9-497.e15. PubMed ID: 33766467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
    Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
    Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.
    Liu C; Shi B; Hao C; Wang Q; Lv Q; Xing N; Shou J; Qu L; Gao Y; Qin C; Zhao J; Shou C
    Oncotarget; 2016 Jul; 7(28):43432-43441. PubMed ID: 27223068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary levels of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein as a diagnostic biomarker in patients with bladder cancer.
    Nitta Y; Konishi H; Makino T; Tanaka T; Kawashima H; Iovanna JL; Nakatani T; Kiyama H
    BMC Urol; 2012 Sep; 12():24. PubMed ID: 22943287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.
    Liu B; Miyake H; Nishikawa M; Fujisawa M
    Urol Oncol; 2015 Mar; 33(3):110.e11-8. PubMed ID: 25262382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL1 is elevated in the urine of bladder cancer patients.
    Burnier A; Shimizu Y; Dai Y; Nakashima M; Matsui Y; Ogawa O; Rosser CJ; Furuya H
    Springerplus; 2015; 4():610. PubMed ID: 26543745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase activity in urine after transurethral resection of superficial bladder cancer and early recurrence.
    Wu XX; Kakehi Y; Takahashi T; Habuchi T; Ogawa O
    Int J Urol; 2000 Jun; 7(6):210-7. PubMed ID: 10843452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
    Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
    Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
    Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
    OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma.
    Li LY; Yang M; Zhang HB; Su XK; Xu WF; Chen Y; Shen ZJ; Gao X
    BJU Int; 2008 Aug; 102(5):566-71. PubMed ID: 18410436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis.
    Dong F; Shen Y; Xu T; Wang X; Gao F; Zhong S; Chen S; Shen Z
    World J Surg Oncol; 2018 Mar; 16(1):61. PubMed ID: 29562940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine tenascin‑C is an independent risk factor for bladder cancer patients.
    Guan Z; Zeng J; Wang Z; Xie H; Lv C; Ma Z; Xu S; Wang X; He D; Li L
    Mol Med Rep; 2014 Mar; 9(3):961-6. PubMed ID: 24366195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.
    Yafi FA; Brimo F; Steinberg J; Aprikian AG; Tanguay S; Kassouf W
    Urol Oncol; 2015 Feb; 33(2):66.e25-31. PubMed ID: 25037483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.